Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Substitute for f	orm 14	49/PTO	Complete if Known				
	INFORMATION	DISC	LOSURE	Application Number	10/584,345	- 2000		
STATEMENT BY APPLICANT				Filing Date	12/24/2004	DEC 1 1 5008		
	Date Submitted: December 11, 2008			First Named Inventor	Nobuaki TAKAHASHI	13		
	Date Submitted: D	ecemo	ei 11, 2006	Art Unit	1644	Sh. at		
(use as many sheets as necessary)				Examiner Name	Phillip Gambel	TRADENM		
neet	1	of	2	Attorney Docket Number	081356-0262			

		U.S. PATENT DO	CUMENTS	
Cito	Document Number	Publication Date MM-DD-YYYY	Name of Datastas as Assissant of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
No.1	Number-Kind Code ² (if known)		Cited Document	
C1	7,262,278 B2	8/28/2007	Tomonori TAWARA et al.	
C2	2003/0059427 A1	3/27/2003	Walker R. FORCE et al.	
	C1_	Cite No. 1 Number-Kind Code ² (if known) C1 7,262,278 B2	Cite No. ¹ Document Number Publication Date MM-DD-YYYY C1 7,262,278 B2 8/28/2007	Cite Publication Date Name of Patentee or Applicant of Number-Kind Code ³ (/f Inown) M-D-YMY Name of Patentee or Applicant of Cited Document C

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear	⊤ 6				
	СЗ	WO 03/033538 A1	4/24/2003	KIRIN BEER KABUSHIKI KAISHA						
	C4	WO 88/07089	9/22/1988	MEDICAL RESEARCH COUNCIL						
	C5	EP 0 314 161 A1	S/3/1989	BRISTOL-MYERS COMPANY						
	C6	EP 1 369 431 A1	12/10/2003	KIRIN BEER KABUSHIKA KAISHA						
	C7	WO 00/61637	10/19/2000	SMITHKLINE BEECHAM CORPORATION						
	C8	WO 00/18804	4/6/2000	SMITHKLINE BEECHAM CORPORATION et al.						
	С9	WO 99/SS369	11/4/1999	SMITHKLINE BEECHAM CORPORATION						
	C10	JP-3101690	8/25/2000			No				

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s) publisher, city and/or country where published.							
	C11	Russian Office Action 2006126979 w/Translation.						
	C12	Japanese Office Action JP 2005-S16724 dated September 9, 2008.	No					
	C13	Supplementary Partial European Search Report EP 04 80 8100 dated July 24, 2008.	-					
	C14	L.G. PRESTA et al., "Engineering Therapeutic Antibodies for Improved Function", Biochemical Society Transactions (2002), Vol. 30, part 4, 2002, pp. 487—490.						

Examiner Signature	/Phillip Gambel/	Date Considered	08/16/2009				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not							

considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Transiation is allached.

Transiation is allached.

Transiation is allached.

Transiation is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complicate including plateming, preparing, and submitting the complicated application form to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing his burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. P.O. 80x 1496, Alexandra, V.A. 2331-1450, DO. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS IND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10584345 TO/ Bak lobio 1644

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for fe	orm 14	19/PTO	Complete if Known		
	INFORMATION	DISCL	.OSURE	Application Number	10/584,345	
	STATEMENT B	Y APP	LICANT	Filing Date	12/24/2004	
	Date Submitted: De	acamb	or 11 2009	First Named Inventor	Nobuaki TAKAHASHI	
	Date Submitted. Di	cemb	ei 11, 2006	Art Unit	1644	
	(use as many shee	ets as i	necessary)	Examiner Name	Phillip Gambel	
Sheet	2	of	2	Attorney Docket Number	081356-0262	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of to Item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue numbe published.					
	C15	Leonard G. PRESTA, "Engineering Antibodies for Therapy", Current Pharmaceutical Biotechnology 2002, 3, 237—256.				
	C16	Ole Henrik BREKKE et al., "Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytes", Eur. J. Immunol.1994, 24: 2542—2547.				
	C17	EP Office Action 04 808 100.4 -2402 dated 11/11/2008				
			-			

Examiner Signature	/Phillip Gambel/	Da Co	ate onsidered	08/16/2009

"EXAMINET: Initial if reference consistence, whether or not classion is in conformance with MPEP 639. Draw ine through classion if no in conformance and not considered, include copy of this form with next communication to applicant 1 Applicant's unique classion delayapian unturely copional) 2 see Kinds Codes of USPTO Patent Documents at www.uspta.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST3, 4 For Jaganese patient document, be indication of the year of the region of the Empireer must precede the sental number of the patient document by the appropriate symbols as indicated on the document unture WIPO Standard ST.16 if possible, 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentishly to spowered by 55 U.S. C122 and 37 CPR 1.14. This collection is estimated to take two completes including pathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this budger, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1459, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: